$JATT

Talawar Therapeutics to Go Public via Business Combination With JATT

Talawar Therapeutics and JATT II Acquisition (JATT) on Monday entered into a definitive business combination agreement that will take Talawar public, with the combined company expected to trade on the Nasdaq Capital Market under the ticker symbol "TLWR".The transaction is expected to close in the second half of 2026. The combined company expects to receive about $285 million in proceeds, including a $225 million private investment in public equity led by Access Biotechnology.The proceeds are expected to fund lead candidate TALA-125 through a phase 2b proof-of-concept data readout in the second half of 2028.TALA-125, a treatment candidate for atopic dermatitis, is expected to enter the clinic in the first quarter of 2027, with interim phase 1 data anticipated in the fourth quarter of 2027.Price: $11.00, Change: $+0.56, Percent Change: +5.39%